Haleon PLC
HLN9.667USD
+0.237+2.51%
Market hours （ET）Quotes delayed by 15 min
87.52BMarket Cap
60.69P/E TTM
More Details of Haleon PLC Company
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Company Info
Ticker SymbolHLN
Company nameHaleon PLC
IPO dateJul 18, 2022
Founded at2021
CEOMr. Brian Mcnamara
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJul 18
AddressBuilding 5, First Floor
CityWEYBRIDGE
Stock exchangeLondon Stock Exchange
CountryUnited Kingdom
Postal codeKT13 0NY
Phone441932822000
Websitehttps://www.haleon.com/
Ticker SymbolHLN
IPO dateJul 18, 2022
Founded at2021
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
444.67K
+0.83%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Matt Shattock
Mr. Matt Shattock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Ms. Tracy Clarke
Ms. Tracy Clarke
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Sir Dave Lewis
Sir Dave Lewis
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Keith Choy
Mr. Keith Choy
President, Asia Pacific
President, Asia Pacific
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
444.67K
+0.83%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Matt Shattock
Mr. Matt Shattock
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: GBPUpdated: Sun, Jul 6
Currency: GBPUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessGBP
Name
Revenue
Proportion
Oral health
880.00M
30.84%
Pain relief
661.00M
23.17%
Respiratory health
465.00M
16.30%
Digestive health and other
431.00M
15.11%
Vitamins, minerals and supplements
416.00M
14.58%
By RegionGBP
Name
Revenue
Proportion
EMEA and LatAm
1.19B
41.64%
Northern America
980.00M
34.35%
APAC
685.00M
24.01%
By Business
By Region
By BusinessGBP
Name
Revenue
Proportion
Oral health
880.00M
30.84%
Pain relief
661.00M
23.17%
Respiratory health
465.00M
16.30%
Digestive health and other
431.00M
15.11%
Vitamins, minerals and supplements
416.00M
14.58%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dodge & Cox
3.77%
Fidelity Management & Research Company LLC
2.16%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.51%
UBS Financial Services, Inc.
0.32%
Other
92.51%
Shareholders
Shareholders
Proportion
Dodge & Cox
3.77%
Fidelity Management & Research Company LLC
2.16%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.51%
UBS Financial Services, Inc.
0.32%
Other
92.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.93%
Investment Advisor
5.10%
Hedge Fund
0.89%
Research Firm
0.50%
Bank and Trust
0.15%
Family Office
0.07%
Family Office
0.06%
Family Office
0.06%
Individual Investor
0.02%
Other
87.23%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1043
571.37M
12.71%
-195.52M
2025Q1
1077
574.94M
12.79%
-194.57M
2024Q4
1094
745.67M
16.47%
-9.34M
2024Q3
1096
717.29M
15.74%
-81.04M
2024Q2
1078
719.27M
15.75%
-155.43M
2024Q1
1041
707.36M
15.49%
-53.58M
2023Q4
993
691.96M
14.98%
-58.05M
2023Q3
933
688.70M
14.92%
-37.88M
2023Q2
891
677.74M
14.68%
-44.11M
2023Q1
842
667.68M
14.46%
-14.30M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dodge & Cox
169.15M
3.77%
-9.59M
-5.37%
Mar 31, 2025
Fidelity Management & Research Company LLC
97.16M
2.16%
+2.47M
+2.61%
Mar 31, 2025
ClearBridge Investments, LLC
32.59M
0.73%
-208.31K
-0.64%
Mar 31, 2025
Harding Loevner LP
23.07M
0.51%
-1.05M
-4.37%
Mar 31, 2025
UBS Financial Services, Inc.
14.33M
0.32%
+7.63M
+113.98%
Mar 31, 2025
Fidelity Institutional Asset Management
14.29M
0.32%
+153.75K
+1.09%
Mar 31, 2025
Wellington Management Company, LLP
18.70M
0.42%
+3.37M
+22.00%
Mar 31, 2025
Sculptor Capital Management, Inc
10.85M
0.24%
+1.96M
+22.09%
Mar 31, 2025
Aristotle Capital Management, LLC
8.44M
0.19%
-314.11K
-3.59%
Mar 31, 2025
Douglas C. Lane & Associates
8.18M
0.18%
-431.27K
-5.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
VanEck Pharmaceutical ETF
5.25%
Franklin ClearBridge Enhanced Income ETF
2.13%
Fidelity Blue Chip Value ETF
0.92%
One Global ETF
0.91%
ActivePassive International Equity ETF
0.46%
SP Funds S&P World (ex-US) ETF
0.36%
Avantis International Equity ETF
0.12%
Avantis Responsible International Equity ETF
0.11%
Avantis International Large Cap Value ETF
0%
Knowledge Leaders Developed World ETF
0%
View more
VanEck Pharmaceutical ETF
Proportion5.25%
Franklin ClearBridge Enhanced Income ETF
Proportion2.13%
Fidelity Blue Chip Value ETF
Proportion0.92%
One Global ETF
Proportion0.91%
ActivePassive International Equity ETF
Proportion0.46%
SP Funds S&P World (ex-US) ETF
Proportion0.36%
Avantis International Equity ETF
Proportion0.12%
Avantis Responsible International Equity ETF
Proportion0.11%
Avantis International Large Cap Value ETF
Proportion0%
Knowledge Leaders Developed World ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Aug 01, 2024
HLN.NB Final Cash Dividend of gross USD 0.051416 paid on Sep 19, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 19, 2024
Aug 16, 2024
Feb 29, 2024
HLN.NB Interim Cash Dividend of gross USD 0.105268 paid on May 16, 2024 going ex on Mar 14, 2024
Mar 15, 2024
May 16, 2024
Mar 14, 2024
Aug 02, 2023
HLN.NB Final Cash Dividend of gross USD 0.043871 paid on Oct 05, 2023 going ex on Aug 24, 2023
Aug 25, 2023
Oct 05, 2023
Aug 24, 2023
Mar 02, 2023
HLN.NB Interim Cash Dividend of gross USD 0.059732 paid on Apr 27, 2023 going ex on Mar 16, 2023
Mar 17, 2023
Apr 27, 2023
Mar 16, 2023
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
